Rigel Pharmaceuticals (NASDAQ: RIGL) on Tuesday, soared 8.73% from the previous trading day, before settling in for the closing price of $42.51. Within the past 52 weeks, RIGL’s price has moved between $14.63 and $43.72.
The company achieved an average annual earnings per share of 544.92%. With a float of $17.67 million, this company’s outstanding shares have now reached $18.14 million.
Rigel Pharmaceuticals (RIGL) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Rigel Pharmaceuticals is 2.65%, while institutional ownership is 82.74%. The most recent insider transaction that took place on Feb 04 ’25, was worth 42,595. In this transaction EVP & Chief Financial Officer of this company sold 2,036 shares at a rate of $20.92, taking the stock ownership to the 58,969 shares. Before that another transaction happened on Feb 05 ’25, when Company’s EVP & Chief Financial Officer sold 1,734 for $21.93, making the entire transaction worth $38,020. This insider now owns 57,235 shares in total.
Rigel Pharmaceuticals (RIGL) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported 0.8 earnings per share (EPS) for the period topping the consensus outlook (set at 0.58) by 0.22. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.62 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 544.92% per share during the next fiscal year.
Rigel Pharmaceuticals (NASDAQ: RIGL) Trading Performance Indicators
Rigel Pharmaceuticals (RIGL) is currently performing well based on its current performance indicators. A quick ratio of 2.14 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.97. Likewise, its price to free cash flow for the trailing twelve months is 12.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 6.17, a number that is poised to hit 1.00 in the next quarter and is forecasted to reach 4.11 in one year’s time.
Technical Analysis of Rigel Pharmaceuticals (RIGL)
Rigel Pharmaceuticals (NASDAQ: RIGL) saw its 5-day average volume 0.71 million, a positive change from its year-to-date volume of 0.4 million. As of the previous 9 days, the stock’s Stochastic %D was 97.99%.
During the past 100 days, Rigel Pharmaceuticals’s (RIGL) raw stochastic average was set at 99.68%, which indicates a significant increase from 99.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.69 in the past 14 days, which was higher than the 1.77 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $32.43, while its 200-day Moving Average is $25.09. Nevertheless, the first resistance level for the watch stands at $48.01 in the near term. At $49.80, the stock is likely to face the second major resistance level. The third major resistance level sits at $53.29. If the price goes on to break the first support level at $42.73, it is likely to go to the next support level at $39.24. The third support level lies at $37.45 if the price breaches the second support level.
Rigel Pharmaceuticals (NASDAQ: RIGL) Key Stats
Market capitalization of the company is 838.95 million based on 18,151K outstanding shares. Right now, sales total 179,280 K and income totals 17,490 K. The company made 69,460 K in profit during its latest quarter, and 27,900 K in sales during its previous quarter.
